ALCULUMBRE SOLANA G ET AL: "Diversification of human plasmacytoid predendritic cells in response to a single stimulus.", NATURE IMMUNOLOGY JAN 2018, vol. 19, no. 1, January 2018 (2018-01), pages 63-75, ISSN: 1529-2916 (B1)

ZOU W ET AL: "Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.", NATURE MEDICINE DEC 2001, vol. 7, no. 12, December 2001 (2001-12), pages 1339-1346, ISSN: 1078-8956 (B1)

BATES P J ET AL: "Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 10 SEP 1999, vol. 274, no. 37, 10 September 1999 (1999-09-10), pages 26369-26377, ISSN: 0021-9258 (B1)

BUTT ET AL.: 'Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines''.' ONCOGENE vol. 33, no. 38, 18 September 2013, pages 4623 - 4631, XP055257733 DOI: 10.1038/ONC.2013.432 (B1)

CHAN MEI PO ET AL: "DNase II-dependent DNA digestion is required for DNA sensing by TLR9.", NATURE COMMUNICATIONS 20 JAN 2015, vol. 6, 20 January 2015 (2015-01-20), page 5853, ISSN: 2041-1723 (B1)

CONRAD CURDIN ET AL: "Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells.", CANCER RESEARCH 15 OCT 2012, vol. 72, no. 20, 15 October 2012 (2012-10-15), pages 5240-5249, ISSN: 1538-7445 (B1)

FAGET JULIEN ET AL: "ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.", CANCER RESEARCH 01 DEC 2012, vol. 72, no. 23, 1 December 2012 (2012-12-01), pages 6130-6141, ISSN: 1538-7445 (B1)

GUIDUCCI CRISTIANA ET AL: "Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation.", THE JOURNAL OF EXPERIMENTAL MEDICINE 07 AUG 2006, vol. 203, no. 8, 7 August 2006 (2006-08-07), pages 1999-2008, ISSN: 0022-1007 (B1)

HARTMANN EVELYN ET AL: "Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.", CANCER RESEARCH 01 OCT 2003, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6478-6487, ISSN: 0008-5472 (B1)

HONDA KENYA ET AL: "Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction.", NATURE 21 APR 2005, vol. 434, no. 7036, 21 April 2005 (2005-04-21), pages 1035-1040, ISSN: 1476-4687 (B1)

KATSUDA MASAHIRO ET AL: "Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.", INTERNATIONAL JOURNAL OF ONCOLOGY NOV 2011, vol. 39, no. 5, November 2011 (2011-11), pages 1295-1302, ISSN: 1791-2423 (B1)

KIM Y H ET AL: "Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 63, no. 6, 1 December 2010 (2010-12-01), pages 975-983, XP027499048, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2009.12.052 [retrieved on 2010-11-18] (B1)

KORTYLEWSKI ET AL.: 'In vivo delivery of sirNA to immune cells by conjugation to a tlr9 agonist enhances antitumor immune responses''.' NATURE BIOTECHNOLOGY vol. 27, no. 10, 01 October 2009, pages 925 - 932, XP055460942 DOI: 10.1038/NBT.1564 (B1)

KRUG A ET AL: "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.", EUROPEAN JOURNAL OF IMMUNOLOGY JUL 2001, vol. 31, no. 7, July 2001 (2001-07), pages 2154-2163, ISSN: 0014-2980 (B1)

KRUG ET AL.: 'Identification of CpG oligonucleotide sequences with high induction of IFN-aip in plasmacytoid dendritic cells''.' EUROPEAN JOURNAL OF IMMUNOLOGY vol. 31, no. 7, 01 July 2001, pages 2154 - 2163, XP002292085 DOI: 10.1002/1521-4141(200107)31:72154::AID-IMMU 2154>3.0.CO;2-U (B1)

LABIDI-GALY SANA INTIDHAR ET AL: "Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.", CANCER RESEARCH 15 AUG 2011, vol. 71, no. 16, 15 August 2011 (2011-08-15), pages 5423-5434, ISSN: 1538-7445 (B1)

LEMKE CAITLIN D ET AL: "Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist - Abstract 3023", BLOOD, & 58TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 03 -06, 2016, vol. 128, no. 22, 2 December 2016 (2016-12-02), XP002771299, (B1)

MANGSBO SARA M ET AL: "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 33, no. 3, 1 April 2010 (2010-04-01), pages 225-235, XP009144370, ISSN: 1524-9557 (B1)

MASON K A ET AL: "Molecular targeting of toll-like receptor 9 with CpG oligodeoxynucleotides (ODN) for enhancement of tumor radioresponse", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYS, PERGAMON PRESS, USA, vol. 60, no. 1, 1 September 2004 (2004-09-01), page S346, XP004557674, ISSN: 0360-3016 (B1)

PENG GUANGYONG ET AL: "Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.", SCIENCE (NEW YORK, N.Y.) 26 AUG 2005, vol. 309, no. 5739, 26 August 2005 (2005-08-26), pages 1380-1384, ISSN: 1095-9203 (B1)

QI XU-FENG ET AL: "CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 54, no. 3, 26 January 2013 (2013-01-26), pages 327-337, XP028998721, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2013.01.001 (B1)

ROTHENFUSSER SIMON ET AL: "CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.", BLOOD 15 MAR 2004, vol. 103, no. 6, 15 March 2004 (2004-03-15), pages 2162-2169, ISSN: 0006-4971 (B1)

SHEN WEIYIN ET AL: "Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis.", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT JUN 2002, vol. 12, no. 3, June 2002 (2002-06), pages 155-164, ISSN: 1087-2906 (B1)

SISIRAK VANJA ET AL: "Impaired IFN-[alpha] production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.", CANCER RESEARCH 15 OCT 2012, vol. 72, no. 20, 15 October 2012 (2012-10-15), pages 5188-5197, ISSN: 1538-7445 (B1)

STEFAN NIERKENS ET AL: "Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice", PLOS ONE, vol. 4, no. 12, 1 January 2009 (2009-01-01), pages e8368-e8368, XP055042111, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0008368 (B1)

US-A1- 2009 082 295 (B1)

US-A1- 2012 251 494 (B1)

WATKINS STEPHANIE K ET AL: "FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.", THE JOURNAL OF CLINICAL INVESTIGATION APR 2011, vol. 121, no. 4, April 2011 (2011-04), pages 1361-1372, ISSN: 1558-8238 (B1)

WO-A2-03/024481 (B1)

WO-A2-2012/006634 (B1)

WONG R M ET AL: "TLR-9 signaling and TCR stimulation co-regulate CD8+ T cell-associated PD-1 expression", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 127, no. 1, 2 December 2009 (2009-12-02), pages 60-67, XP026745618, ISSN: 0165-2478, DOI: 10.1016/J.IMLET.2009.09.002 [retrieved on 2009-09-12] (B1)

ASSAF A ET AL: "A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 259, no. 1, 1 January 2009 (2009-01-01), pages 90-99, XP026459070, ISSN: 0008-8749 [retrieved on 2009-06-06] (B1)